A phase I/II trial of TAS-102 in combination with irinotecan in Japanese patients with advanced gastric cancer refractory to standard chemotherapies
Phase 1
- Conditions
- advanced gastric cancer refractory to standard chemotherapies
- Registration Number
- JPRN-UMIN000031346
- Lead Sponsor
- St. Marianna University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 11
Inclusion Criteria
Not provided
Exclusion Criteria
- With a treatment history of TAS-102 or irinotecan - Serious illness such as brain metastasis, systemic infection or gastrointestinal bleeding - Medical treatment such as major surgery within 4 weeks, systemic chemotherapy within 2 weeks - Adverse events due to prior chemotherapy - Administration of blood transfusion or G-CSF within 2 weeks - Severe pulmonaly disorder - Thromboembolism (grade3 or higher) within 6 months - Inappropriate for the study in the opinion of the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method